Learning from the TGN1412 trial
- PMID: 16554332
- PMCID: PMC1410845
- DOI: 10.1136/bmj.38797.635012.47
Learning from the TGN1412 trial
Abstract
This experience should foster an open culture in medical research
References
-
- Pearson H. Tragic drug trial spotlights potent molecule. Nature doi: 10.1038/news060313-17 (published 17 March 2006). - DOI
-
- Beyersdorf N, Hanke T, Kerkau T, Hunig T. CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmun Rev 2006;5: 40-5. - PubMed
-
- Kennedy I. Learning from Bristol: the report of the public inquiry into children's heart surgery at the Bristol Royal Infirmary 1984-1995. London: Stationery Office, 2001. (Cm 5207.)
-
- Merton RK. Unanticipated consequences of purposive social action. Am Sociol Rev 1936;1:894-904. www.compilerpress.atfreeweb.com/Anno%20Merton%20Unintended.htm (accessed 21 Mar 2006).
-
- Oakeshott I, Rogers L. Earlier trials had shown that drug group was highly toxic. Sunday Times 2006 Mar 19. www.timesonline.co.uk/article/0,,2087-2092619,00.html (accessed 21 Mar 2006).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources